Clinical Trials Logo

Clinical Trial Summary

This non-interventional, epidemiological study assesses long-term outcomes in subjects receiving immunoglobulins (IgG) for any treatment purpose, irrespective of the regimen prescribed by the treating physician, under routine clinical conditions in Germany.

Long-term outcome data are collected on patient characteristics in the various indications, drug utilization of intravenous and subcutaneous IgG (e.g. treatment and dosing patterns), effectiveness (i.e. number of infections), tolerability, health related quality of life, and economic variables (number of hospitalizations, sick-leave days etc.) with the possibility to estimate direct costs.


Clinical Trial Description

In view of the broad range of indications in immunodeficiency and immunomodulation, it is of interest to document the use of IgG under the conditions of everyday practice and to analyze the endpoints (outcomes). A prospective cohort study such as this is an important evidence source for such rare diseases as those mentioned above. The aim of this outcome study is to fill the gap of the lack of long-term data in these rare diseases treated with IgG. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01287689
Study type Observational [Patient Registry]
Source Technische Universität Dresden
Contact
Status Completed
Phase N/A
Start date July 2010
Completion date December 31, 2016

See also
  Status Clinical Trial Phase
Recruiting NCT01962415 - Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT Phase 2
Completed NCT00751621 - Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study) Phase 3
Recruiting NCT04528355 - Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
Completed NCT02180763 - Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps Phase 4
Completed NCT00391131 - Subcutaneous Ig NextGen 16% in PID Patients Phase 3